ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
107,978.68
4.72%
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs Yen
156.356
0.02%
Brent Oil
79.655
-0.70%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) ニュース

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:GLUE
日付受信時刻ニュースソース見出しコード企業名
2025/01/1021 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/1021 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025NASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0706 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2025/01/0621 : 00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1323 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1323 : 00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1321 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1321 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1121 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/1121 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/0521 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/12/0521 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/11/2621 : 00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/11/1321 : 00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/11/0721 : 07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/11/0721 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/11/0721 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/10/2820 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/10/2819 : 59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/10/2320 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/09/1405 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/08/2820 : 00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/08/1920 : 00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyNASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/08/0820 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
2024/08/0820 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GLUE

最近閲覧した銘柄

COIN
LATXGBP
LatiumX
BOV
HAGA3R
HAGA ON
BIT
S28719
Societe Generale Effekten
BOV
CYRE3R
CYRELA REALT ON
BIT
S31338
Societe Generale Effekten
LSE
ELX
El Oro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有